(1R,2R)-2-(7-((5-Chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl)-methyl)-2-methyl-5-oxo-5H-thiazolo[3,2-a]pyrimidin-3-yl)-cyclopropanecarbonitrile

ID: ALA3799878

Chembl Id: CHEMBL3799878

PubChem CID: 127045915

Max Phase: Preclinical

Molecular Formula: C16H11ClF3N5OS

Molecular Weight: 413.81

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1sc2nc(Cn3nc(C(F)(F)F)cc3Cl)cc(=O)n2c1[C@@H]1C[C@H]1C#N

Standard InChI:  InChI=1S/C16H11ClF3N5OS/c1-7-14(10-2-8(10)5-21)25-13(26)3-9(22-15(25)27-7)6-24-12(17)4-11(23-24)16(18,19)20/h3-4,8,10H,2,6H2,1H3/t8-,10+/m0/s1

Standard InChI Key:  SQALNDKGODGXJT-WCBMZHEXSA-N

Alternative Forms

  1. Parent:

    ALA3799878

    ---

Associated Targets(Human)

GRIN1 Tclin Glutamate NMDA receptor; GRIN1/GRIN2A (719 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GRIA2 Tclin Glutamate receptor ionotropic, AMPA 2 (847 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

MDCK (10148 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 413.81Molecular Weight (Monoisotopic): 413.0325AlogP: 3.61#Rotatable Bonds: 3
Polar Surface Area: 75.98Molecular Species: NEUTRALHBA: 7HBD: 0
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 2.73CX LogD: 2.73
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.66Np Likeness Score: -1.69

References

1. Volgraf M, Sellers BD, Jiang Y, Wu G, Ly CQ, Villemure E, Pastor RM, Yuen PW, Lu A, Luo X, Liu M, Zhang S, Sun L, Fu Y, Lupardus PJ, Wallweber HJ, Liederer BM, Deshmukh G, Plise E, Tay S, Reynen P, Herrington J, Gustafson A, Liu Y, Dirksen A, Dietz MG, Liu Y, Wang TM, Hanson JE, Hackos D, Scearce-Levie K, Schwarz JB..  (2016)  Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.,  59  (6): [PMID:26919761] [10.1021/acs.jmedchem.5b02010]
2. Villemure E, Volgraf M, Jiang Y, Wu G, Ly CQ, Yuen PW, Lu A, Luo X, Liu M, Zhang S, Lupardus PJ, Wallweber HJ, Liederer BM, Deshmukh G, Plise E, Tay S, Wang TM, Hanson JE, Hackos DH, Scearce-Levie K, Schwarz JB, Sellers BD..  (2017)  GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved in Vivo Profile.,  (1): [PMID:28105280] [10.1021/acsmedchemlett.6b00388]

Source